JP2022513913A - がん免疫療法のためのラビリンチンベースのペプチドとその使用 - Google Patents

がん免疫療法のためのラビリンチンベースのペプチドとその使用 Download PDF

Info

Publication number
JP2022513913A
JP2022513913A JP2021534341A JP2021534341A JP2022513913A JP 2022513913 A JP2022513913 A JP 2022513913A JP 2021534341 A JP2021534341 A JP 2021534341A JP 2021534341 A JP2021534341 A JP 2021534341A JP 2022513913 A JP2022513913 A JP 2022513913A
Authority
JP
Japan
Prior art keywords
seq
peptide
labyrinthine
variant
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021534341A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022513913A5 (https=
Inventor
ジェームズ エー． ラドセビッチ，
マイケル バビッチ，
Original Assignee
ラビアールエックス イミュノロジック セラピューティクス （ユーエスエー） リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ラビアールエックス イミュノロジック セラピューティクス （ユーエスエー） リミテッド filed Critical ラビアールエックス イミュノロジック セラピューティクス （ユーエスエー） リミテッド
Publication of JP2022513913A publication Critical patent/JP2022513913A/ja
Publication of JP2022513913A5 publication Critical patent/JP2022513913A5/ja
Priority to JP2025003947A priority Critical patent/JP2025072379A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/13—B-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0819—Tripeptides with the first amino acid being acidic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/101—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2021534341A 2018-12-13 2019-12-13 がん免疫療法のためのラビリンチンベースのペプチドとその使用 Pending JP2022513913A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025003947A JP2025072379A (ja) 2018-12-13 2025-01-10 がん免疫療法のためのラビリンチンベースのペプチドとその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862779377P 2018-12-13 2018-12-13
US62/779,377 2018-12-13
PCT/US2019/066264 WO2020123964A1 (en) 2018-12-13 2019-12-13 Labyrinthin-based peptides for cancer immunotherapies and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025003947A Division JP2025072379A (ja) 2018-12-13 2025-01-10 がん免疫療法のためのラビリンチンベースのペプチドとその使用

Publications (2)

Publication Number Publication Date
JP2022513913A true JP2022513913A (ja) 2022-02-09
JP2022513913A5 JP2022513913A5 (https=) 2022-12-21

Family

ID=71077093

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021534341A Pending JP2022513913A (ja) 2018-12-13 2019-12-13 がん免疫療法のためのラビリンチンベースのペプチドとその使用
JP2025003947A Pending JP2025072379A (ja) 2018-12-13 2025-01-10 がん免疫療法のためのラビリンチンベースのペプチドとその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025003947A Pending JP2025072379A (ja) 2018-12-13 2025-01-10 がん免疫療法のためのラビリンチンベースのペプチドとその使用

Country Status (11)

Country Link
US (1) US20220409709A1 (https=)
EP (1) EP3894432A4 (https=)
JP (2) JP2022513913A (https=)
KR (2) KR20260042221A (https=)
CN (1) CN113412275A (https=)
AU (1) AU2019397539B2 (https=)
CA (1) CA3123396A1 (https=)
IL (1) IL283933A (https=)
MX (1) MX2021007074A (https=)
TW (1) TW202039536A (https=)
WO (1) WO2020123964A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116143868B (zh) * 2023-01-10 2025-10-21 合肥工业大学 一种能够增强咸味的多肽及其应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04502013A (ja) * 1989-05-03 1992-04-09 コノート　ラボラトリーズ　リミテッド Ｈｉｖ―１ワクチンのための合成ペプチド
JP2002512005A (ja) * 1998-03-17 2002-04-23 ジェイムズ エイ． ラドセビッチ， ガンについてのマーカーである、ラビリンチンをコードする遺伝子
US20030021798A1 (en) * 1999-04-12 2003-01-30 Immtech International Inc. Use of mCRP to enhance immune responses
JP2009525047A (ja) * 2006-02-02 2009-07-09 ザ ユーエイビー リサーチ ファウンデイション 肺炎レンサ球菌表面タンパク質ｐｓｐａおよびｐｓｐｃの非−コイル保護領域
WO2011116014A2 (en) * 2010-03-15 2011-09-22 Mission Therapeutics, Inc. Humanized antibodies to labyrinthin and uses thereof
JP2013525271A (ja) * 2010-03-12 2013-06-20 チルドレンズ メディカル センター コーポレーション 免疫原およびそのスクリーニング方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2607374A1 (en) * 2011-12-21 2013-06-26 Sanofi Method for recombinant production of labyrinthopeptins and functional derivatives thereof
US20200190480A1 (en) * 2017-08-30 2020-06-18 Next Pharma Inc. ANTIBODIES AGAINST ASPARTYL (ASPARAGINYL) beta-HYDROXYLASE (AABH) AND METHODS OF MAKING AND USING

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04502013A (ja) * 1989-05-03 1992-04-09 コノート　ラボラトリーズ　リミテッド Ｈｉｖ―１ワクチンのための合成ペプチド
JP2002512005A (ja) * 1998-03-17 2002-04-23 ジェイムズ エイ． ラドセビッチ， ガンについてのマーカーである、ラビリンチンをコードする遺伝子
US20030021798A1 (en) * 1999-04-12 2003-01-30 Immtech International Inc. Use of mCRP to enhance immune responses
JP2009525047A (ja) * 2006-02-02 2009-07-09 ザ ユーエイビー リサーチ ファウンデイション 肺炎レンサ球菌表面タンパク質ｐｓｐａおよびｐｓｐｃの非−コイル保護領域
JP2013525271A (ja) * 2010-03-12 2013-06-20 チルドレンズ メディカル センター コーポレーション 免疫原およびそのスクリーニング方法
WO2011116014A2 (en) * 2010-03-15 2011-09-22 Mission Therapeutics, Inc. Humanized antibodies to labyrinthin and uses thereof

Also Published As

Publication number Publication date
IL283933A (en) 2021-07-29
KR102929753B1 (ko) 2026-02-24
AU2019397539A1 (en) 2021-07-15
EP3894432A4 (en) 2023-01-25
KR20260042221A (ko) 2026-03-30
CA3123396A1 (en) 2020-06-18
WO2020123964A1 (en) 2020-06-18
US20220409709A1 (en) 2022-12-29
JP2025072379A (ja) 2025-05-09
AU2019397539B2 (en) 2025-04-24
MX2021007074A (es) 2021-10-13
CN113412275A (zh) 2021-09-17
EP3894432A1 (en) 2021-10-20
TW202039536A (zh) 2020-11-01
KR20210131995A (ko) 2021-11-03

Similar Documents

Publication Publication Date Title
Slovin et al. Carbohydrate vaccines as immunotherapy for cancer
Chapman et al. Induction of antibodies against GM2 ganglioside by immunizing melanoma patients using GM2-keyhole limpet hemocyanin+ QS21 vaccine: a dose-response study
Kushner et al. Phase I trial of a bivalent gangliosides vaccine in combination with β-glucan for high-risk neuroblastoma in second or later remission
Krug et al. Vaccination of small cell lung cancer patients with polysialic acid or N-propionylated polysialic acid conjugated to keyhole limpet hemocyanin
Chyu et al. Immunization using ApoB-100 peptide–linked nanoparticles reduces atherosclerosis
Slovin et al. A bivalent conjugate vaccine in the treatment of biochemically relapsed prostate cancer: a study of glycosylated MUC-2-KLH and Globo H-KLH conjugate vaccines given with the new semi-synthetic saponin immunological adjuvant GPI-0100 OR QS-21
Ragupathi et al. A preclinical study comparing approaches for augmenting the immunogenicity of a heptavalent KLH-conjugate vaccine against epithelial cancers
JP2022088665A (ja) がんの治療
BRPI1012890B1 (pt) Composição adjuvante aquosa, composição imunogênica, processo para preparar uma composição imunogênica, e, kit
Livingston et al. Approaches to augmenting the immunogenicity of the ganglioside GM2 in mice: purified GM2 is superior to whole cells.
CN105816867A (zh) 预防乳腺癌复发的疫苗
US20170232085A1 (en) Companion animal treatments
Ciesielski et al. Therapeutic effect of a T helper cell supported CTL response induced by a survivin peptide vaccine against murine cerebral glioma
US9114099B2 (en) Vaccine for the prevention of breast cancer recurrence
JP2024109648A (ja) ネオエピトープを標的とするワクチン
Gerard et al. A comprehensive preclinical model evaluating the recombinant PRAME antigen combined with the AS15 immunostimulant to fight against PRAME-expressing tumors
Ragupathi et al. Constructing an adenocarcinoma vaccine: Immunization of mice with synthetic KH‐1 nonasaccharide stimulates anti‐KH‐1 and anti‐Ley antibodies
JP2025072379A (ja) がん免疫療法のためのラビリンチンベースのペプチドとその使用
Mazumder et al. Primary immunoprevention of epithelial ovarian carcinoma by vaccination against the extracellular domain of anti-Müllerian hormone receptor II
Zhao et al. Different protective efficacies of a novel antigen-specific DNA vaccine encoding chicken type Ⅱ collagen via intramuscular, subcutaneous, and intravenous vaccination against experimental rheumatoid arthritis
Tijtgat et al. Intratumoral administration of the immunologic adjuvant AS01B in combination with autologous CD1c (BDCA-1)+/CD141 (BDCA-3)+ myeloid dendritic cells plus ipilimumab and intravenous nivolumab in patients with refractory advanced melanoma
JP6385280B2 (ja) 自家癌細胞ワクチン
US20190117749A1 (en) PEPTIDE VACCINE THERAPY FOR TREATMENT OF FRa-EXPRESSING TUMORS
Hemstreet III et al. Cellular immunotherapy study of prostate cancer patients and resulting IgG responses to peptide epitopes predicted from prostate tumor-associated autoantigens
RU2607379C2 (ru) Раковый антиген

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221213

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221213

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20231129

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231205

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240301

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240430

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240605

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240910

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250110